tumor immunology Flashcards

(44 cards)

1
Q

prevention of development of most tumors through early destruction of abnormal cells

A

immune surveillance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

immune system in surveillance

A
  • tumors contain lymphoid infiltrate
  • spontaneous regression of tumors
  • tumors high in neonatal and aged and immunocompromised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what percent are non-tumor cells?

A

20-80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

immune surveillance depends on the type of tumor inducing agent..

A
  • viral
  • chemically induced tumors
  • spontaneous mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

viral immune surveillance

A

express new viral antigen that become target for immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

chemically induced tumors immune surveillance

A

highly antigenic by expressing unique antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

spontaneous mutations immune surveillance

A

deletions and rearrangements lead to tumorigenesis

- difficult to respond to because most of the tumor cells have similar antigens as normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the central paradox of tumor immunology?

A

immunological escape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

when does immunological escape occur?

A

balance between factors favoring tumor growth is favored over destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sneak through, not recognize until growth is established

a. tumor kinetics
b. antigenic modulation
c. antigen masking
d. antigen shedding

A

a. tumor kinetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

loss of the determinants leading to removal of target antigens that the immune system’s effectors would recognize

a. tumor kinetics
b. antigenic modulation
c. antigen masking
d. antigen shedding

A

b. antigenic modulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

certain molecules such as sialomucin, bond to membrane masks tumor antigens and prevent recognition

a. tumor kinetics
b. antigenic modulation
c. antigen masking
d. antigen shedding

A

c. antigen masking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

circulating soluble tumor associated antigens capable of compromising t chin of antigen binding sites particularly in the tumor microenvironment

a. tumor kinetics
b. antigenic modulation
c. antigen masking
d. antigen shedding

A

d. antigen shedding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

inhibition of effective immune response by induction of apoptosis of reactive t cells by generation of suppressive cellular and cytokine environment. failure to generate antigen specific t cells

a. tolerance
b. genetic factors
c. inhibitory factors
d. tumor products

A

a. tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

some neoplasm fail to express mhc I antigen. HLA expression is frequently altered in tumors

a. tolerance
b. genetic factors
c. inhibitory factors
d. tumor products

A

b. genetic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

immune complexes generated by binding of shaded tumor antigens with antibodies could block immune response by binding directly to t cells or binding to th cells and preventing them to recognize the tumors and delivering help to cytotoxic t cells

a. tolerance
b. genetic factors
c. inhibitory factors
d. tumor products

A

c. inhibitory factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

secretory products from tumors capable of inhibiting effective immune functions

a. tolerance
b. genetic factors
c. inhibitory factors
d. tumor products

A

d. tumor products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

innate immunity against tumors cells

A
  • NK cells
  • PMNs
  • monocytes/macrophages
  • killer cells
19
Q

Innate immunity against tumors

A

cells can kill tumors spontaneously without prior sensitization

20
Q

Essentially evoked against tumor associated antigens

A

adaptive immune resposne

21
Q

adaptive immune response against tumors cells

A

th cells

cytotoxic cells

22
Q

cytotoxic t cells and tumors

A

recognize tumor antigens in association with MHC products

23
Q

Th cells and tumors

A

after activation produce interleukins which mediate immune response

24
Q

t/f amplification of these responses require an optimal supply of cytokines/interleukins

25
mechanisms responsible for failure to generate antigen specific t cells
- defects in t cells - defects in APCs and antigen presentation - defect in microenvironment
26
defects in APCs and antigen presentation
- absence of co-stim molecules | - checkpoint inhibiton
27
when is immunotherapy effective?
as adjuvant with conventional therapies
28
facilitates the destruction of hard to treat tumor foci which escapes conventional therapies
immunotherapy
29
what should immunotherapy enhance?
specific and non-specific host response
30
what should immunotherapy minimize?
tumor escape
31
use inactivated tumor cells
therapeutic vaccination
32
make tumor cells more immunogenic
therapeutic vaccination
33
correction of MHC expression
therapeutic vaccination
34
immunization with defined peptide in novel adjuvant to generate cytotoxic t cells
therapeutic vaccination
35
recruitment, expansion and target DCs
therapeutic vaccination
36
provenge
therapeutic vaccination
37
immunization against oncogenic viruses
prophylactic vaccination
38
hepatitis b vaccine
prophylactic vaccination
39
monoclonal antibodies are used either alone or coupled to drugs, pro-drugs, toxins, cytokines or isotopes
passive immunotherapy
40
antibodies inhibit neovascularization
avastin
41
limitation to passive immunotherapy
- antibody penetration - antibodies bound to other cells - antibodies immunogenic
42
nivolumab
check point inhibitor
43
when do tumors develop?
when surveillance system breaks down or overwhelmed
44
what will be critical for management of malignant disease?
adjuvant immunotherapy